Trial Profile

Evaluation of Growth, Sexual Maturation, and Prolactin-Related Adverse Events in the Pediatric Population Exposed to Atypical Antipsychotic Drugs.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Risperidone (Primary) ; Antipsychotics
Indications Attention deficit and disruptive behaviour disorders; Autistic disorder; Bipolar disorders; Schizophrenia
Focus Adverse reactions
Sponsors Janssen Research & Development

Most Recent Events

09 Aug 2017 This trial has been discontinued in Belgium, as per European Clinical Trials Database record.
07 Feb 2012 Actual number pf patients changed from 241 to 244 as reported by ClinicalTrials.gov.
11 Oct 2011 Actual initiation date changed from Nov 2009 to Oct 2009 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com